# South Korea Prostate Cancer Market > South Korea Prostate Cancer Market Research Report: Size, Share, Trend Analysis By Types (Prostate Adenocarcinoma, Small Cell Carcinoma), By Component (Therapy, Diagnosis) and By End-User (Specialty Centers, Hospital & Clinics) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.62% - **2024:** $ 183.85 Million - **2025:** $ 197.86 Million - **2035:** $ 412.4 Million - **Key Players:** Astellas Pharma (JP), Bayer AG (DE), Johnson & Johnson (US), Pfizer Inc. (US), Novartis AG (CH), Merck & Co. (US), Sanofi (FR), Ipsen S.A. (FR), Eli Lilly and Company (US) **Report ID:** MRFR/MED/54355-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-prostate-cancer-market-56121 --- ## Market Summary ## **South Korea Prostate Cancer Market Overview** As per MRFR analysis, the South Korea Prostate Cancer Market Size was estimated at 170.74 (USD Million) in 2024.The South Korea Prostate Cancer Market Industry is expected to grow from 183.75(USD Million) in 2025 to 460 (USD Million) by 2035. The South Korea Prostate Cancer Market CAGR (growth rate) is expected to be around 8.7% during the forecast period (2025 - 2035). **Key South Korea Prostate Cancer Market Trends Highlighted** In South Korea, the prostate cancer market is witnessing significant trends that reflect a growing awareness and advancements in treatment options. One of the key market drivers is the increasing prevalence of prostate cancer within the aging male population, leading to heightened screening and diagnostic measures. The South Korean government has been actively promoting health screenings, which include prostate cancer tests, as part of its national health policies. As a result, public awareness campaigns have encouraged men to seek early diagnosis, driving the demand for medical consultations and diagnostic tools.  Opportunities in the South Korea prostate cancer market are emerging with the integration of innovative technologies, such as robotic-assisted surgeries and advanced imaging techniques.These advancements not only improve the precision of treatments but also enhance recovery times for patients. Additionally, the development of targeted therapies and immunotherapies presents an exciting avenue for both pharmaceutical companies and healthcare providers, as these treatments cater to specific cancer types and patient needs. Recent trends indicate a shift towards personalized medicine in the management of prostate cancer in South Korea.  With ongoing research and development, there is a focus on tailoring treatment plans based on genetic profiling and biomarkers, which can lead to more effective and individualized care. Collaborations between South Korean universities and biotech firms are fostering innovation in this field, aiming to enhance patient outcomes.Furthermore, the rising importance of patient support systems, including counseling and survivorship programs, is becoming increasingly recognized, reflecting a patient-centered approach in the healthcare system that complements emerging treatment modalities. Source: Primary**Research, Secondary Research, MRFR Database and Analyst Review** **South Korea Prostate Cancer Market Drivers** **Increasing Incidence of Prostate Cancer** The South Korea Prostate Cancer Market Industry is significantly driven by the increasing incidence of prostate cancer within the country. Recent statistics from the Korean National Cancer Center indicate that prostate cancer cases have risen by approximately 25% over the last decade, making it the most prevalent cancer among men in South Korea. This alarming rise correlates with the aging population in South Korea, where over 14% of the population is currently aged 65 or older. Consequently, the need for prostate cancer diagnostic and treatment services is anticipated to grow in the future. Also, some of the already existing bodies, like the Korea Prostate Society, are proactive in promoting awareness with regard to prostate health, which helps in the advancement of the market. More men are likely to go for screening and treatment, which, along with better outreach and support, will reinforce the market's upward trajectory. **Advancements in Diagnostic Technologies** Technological advancements in diagnostic tools are a significant driver for the South Korea Prostate Cancer Market Industry. The introduction of advanced imaging techniques such as multiparametric magnetic resonance imaging (MRI) and liquid biopsy has improved early detection rates, enabling more effective diagnosis and treatment planning.  According to the Health Insurance Review and Assessment Service in South Korea, the incorporation of these advanced technologies has resulted in a 30% increase in early-stage prostate cancer detection within the last five years.Major players in the market are investing heavily in Research and Development to enhance these technologies, thus propelling market growth. The South Korean government is also supporting these advancements through funding initiatives aimed at improving cancer care and diagnostics in the nation. **Growing Public Awareness and Screening Programs** Public awareness regarding prostate cancer and the importance of early screening is another key driver for the South Korea Prostate Cancer Market Industry. Campaigns organized by various health organizations and government initiatives have effectively educated the South Korean population about the risks and symptoms of prostate cancer.  For example, the Ministry of Health and Welfare has launched nationwide prostate cancer awareness campaigns aimed at men over the age of 50, which has led to a reported 40% increase in screening participation rates in recent years.This heightened awareness is crucial as it encourages men to seek timely medical advice and treatment options, ultimately leading to an increase in the demand for prostate cancer therapeutics and diagnostics. **Supportive Government Policies and Funding** Supportive government policies and investment in healthcare infrastructure are pivotal drivers of the South Korea Prostate Cancer Market Industry. The South Korean government is committed to improving cancer treatment and prevention through various initiatives, including providing subsidies for prostate cancer screening and treatment. The National Health Insurance Service has expanded coverage for prostate cancer-related treatments significantly, with funding allocations increasing by 15% over the past three years. This financial support encourages more patients to seek treatment, thereby boosting market growth. Furthermore, the government has set ambitious targets to reduce cancer mortality rates, which include specific goals for prostate cancer management. These initiatives align with the overall healthcare improvement strategies in South Korea, further propelling the growth potential of the prostate cancer market. **South Korea Prostate Cancer Market Segment Insights** **Prostate Cancer Market Type Insights** The South Korea Prostate Cancer Market has gained significant attention due to the increasing prevalence of prostate cancer among the male population in the region. Among the various types of prostate cancer, Prostate Adenocarcinoma represents the majority holding regarding cases, making it the most common type and thus a focal point for research and treatment. This cancer type is characterized by its slow growth, allowing for various management strategies, which is crucial given that many patients are diagnosed at an early stage and opt for active surveillance. The healthcare infrastructure in South Korea, alongside advancements in diagnostic technologies, has significantly improved the early detection rates of Prostate Adenocarcinoma, enabling timely intervention. Moreover, Small Cell Carcinoma is a less common but aggressive type of prostate cancer, presenting unique challenges in terms of treatment due to its rapid progression. The need for effective and personalized therapy for managing Small Cell Carcinoma has led to increased investments in innovative therapeutic approaches, including targeted therapy and immunotherapy. As South Korea continues to emphasize healthcare innovation and precision medicine, there is a growing opportunity for advancements in the treatment landscape for both types of prostate cancer. The South Korea Prostate Cancer Market segmentation is likely to benefit from ongoing public health initiatives aimed at raising awareness about prostate health, leading to more men seeking timely medical advice and screening. Furthermore, the aging population in South Korea, which is expected to grow significantly, will likely contribute to an increase in prostate cancer incidences, driving market growth and research into these types over the coming years. Keeping pace with these demographic changes will be essential for effectively addressing the burden of prostate cancer in South Korea. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Prostate Cancer Market Component Insights** The South Korea Prostate Cancer Market has been experiencing notable growth, particularly within the Component segment, which comprises Therapy and Diagnosis. The increasing prevalence of prostate cancer in South Korea, coupled with advancements in treatment technologies, has driven demand in the Therapy segment. Various therapeutic approaches, including hormone therapy and immunotherapy, are gaining traction due to their efficacy and improved patient outcomes.  Meanwhile, the Diagnosis segment is equally important, as early detection significantly enhances treatment success rates.Innovative diagnostic tools and techniques, such as biopsy and imaging, are being adopted, reflecting a growing focus on precision medicine. The emphasis on personalized care is shaping the landscape of the South Korea Prostate Cancer Market, creating opportunities for new developments and partnerships in the industry. Additionally, rising awareness about prostate cancer and government initiatives aimed at improving screening and treatment infrastructure further support this market segment's expansion. Overall, the segmentation in the South Korea Prostate Cancer Market highlights an evolving landscape driven by advancements in both therapeutic and diagnostic capabilities. **Prostate Cancer Market End-User Insights** The South Korea Prostate Cancer Market has seen a remarkable focus on the End-User segment, which primarily includes Specialty Centers, Hospitals, and Clinics. As the prevalence of prostate cancer continues to rise in South Korea, there is an increasing reliance on these healthcare establishments for diagnosis and treatment. Specialty Centers play a crucial role in offering advanced care, utilizing state-of-the-art technologies that are increasingly important given the rising demand for targeted therapies.  Hospitals are also significant contributors to the South Korea Prostate Cancer Market, as they provide comprehensive services, including surgical interventions and radiation therapy, addressing a wide range of patient needs.Clinics, often the first point of contact, focus on early detection and management, facilitating timely interventions that are essential for improving patient outcomes. The growing population of older adults in South Korea further propels the demand for these services, emphasizing the importance of accessibility and quality of care within these facilities. As the market evolves, these End-User segments will continue to dominate, fulfilling critical healthcare needs in the ongoing fight against prostate cancer. **South Korea Prostate Cancer Market Key Players and Competitive Insights** The South Korea Prostate Cancer Market has been witnessing significant developments, driven by increasing awareness of prostate cancer among the aging population and advancements in treatment options. The market is characterized by the presence of a diverse array of pharmaceutical companies and biotechnological firms that contribute to improving the diagnosis and treatment of this prevalent disease. Competitive dynamics in the market are influenced by various factors, including innovative research and development efforts, pricing strategies, and the overall regulatory landscape that governs drug approvals and practices. The collaboration between local players and global entities corroborates the strength of the market, while continuous innovations are required to keep pace with changing treatment paradigms and patient needs. Samsung Biologics has established a prominent presence in the South Korean Prostate Cancer Market through its strong focus on biologics and monoclonal antibodies that target cancer treatment. With a robust infrastructure for biologics manufacturing and research, Samsung Biologics positions itself as a key player by leveraging its advanced technological capabilities. The company’s commitment to innovation in biologics development, coupled with strategic partnerships and collaborations, enhances its capacity to supply effective therapeutic solutions tailored to the needs of prostate cancer patients. Samsung Biologics’ extensive experience in biopharmaceuticals strengthens its market presence in South Korea by providing cutting-edge treatments that aim to address the complexities of prostate cancer management while ensuring compliance with local regulations. Pfizer has maintained a significant foothold in the South Korea Prostate Cancer Market through its extensive portfolio of targeted therapies and hormone treatment options for prostate cancer. The company has established a reputation for delivering reliable and effective treatments to patients, greatly contributing to the improvement of care in South Korea. Pfizer’s key products include a range of inhibitors that target cancer growth, providing innovative solutions that align with current treatment protocols. The company's strong position in the market is further strengthened by strategic mergers and acquisitions that enhance its product offerings and research capabilities. Additionally, Pfizer engages in various initiatives aimed at patient education and support, ensuring it addresses patient and provider needs effectively. This proactive approach, combined with its commitment to maintaining high-quality standards, fosters trust and loyalty within the South Korean healthcare landscape, solidifying its presence in the competitive prostate cancer market. **Key Companies in the South Korea Prostate Cancer Market Include:** - Samsung Biologics - Pfizer - AbbVie - Roche - Johnson & Johnson - BristolMyers Squibb - Novartis - Eli Lilly - Bayer - Merck & Co. - LG Chem - Daewoong Pharmaceutical - Hanmi Pharm - AstraZeneca - Korea United Pharm **South Korea Prostate Cancer Market Industry Developments** Recent developments in the South Korea Prostate Cancer Market have demonstrated significant progress in treatment options and research initiatives. Samsung Biologics is focusing on the development of biologics for prostate cancer therapeutics, while Pfizer and AbbVie continue to expand their portfolios of androgen receptor inhibitors. In October 2023, Roche launched a new immunotherapy that aims to enhance treatment efficacy for advanced prostate cancer patients.  Current affairs indicate a steady growth in the market valuation, driven by increasing prostate cancer prevalence and advancements in targeted therapies. The integration of digital health technologies is becoming prevalent, with companies like Johnson and Johnson and Eli Lilly investing in innovative solutions for patient monitoring and management.  In terms of mergers and acquisitions, Bayer completed its acquisition of a biotech firm specializing in prostate cancer therapies in September 2023, which is anticipated to strengthen its R&D capabilities. Major happenings over the past few years include the establishment of national guidelines in March 2021 for prostate cancer screening and management by the Korean Urological Association, reflecting the government's commitment to improving patient outcomes and bolstering the healthcare infrastructure. **South Korea Prostate Cancer Market Segmentation Insights** **Prostate Cancer Market Type Outlook** - Prostate Adenocarcinoma - Small Cell Carcinoma **Prostate Cancer Market Component Outlook** - Therapy - Diagnosis **Prostate Cancer Market End-User Outlook** - Specialty Centers - Hospital & Clinics ## Market Drivers ### Rising Incidence Rates The prostate cancer market in South Korea is influenced by rising incidence rates of the disease. Recent statistics indicate that prostate cancer cases have increased by approximately 15% over the past five years, making it one of the most common cancers among men in the region. This upward trend is attributed to factors such as an aging population and lifestyle changes. As more individuals are diagnosed, there is a corresponding increase in the demand for treatment options, including surgery, radiation therapy, and hormonal therapies. The growing patient population is likely to drive the prostate cancer market, necessitating the development of new therapies and support services. ### Collaborative Research Efforts Collaborative research efforts among academic institutions, healthcare providers, and pharmaceutical companies are shaping the prostate cancer market in South Korea. These partnerships aim to accelerate the development of new therapies and improve treatment protocols. In 2025, it is anticipated that collaborative projects will increase by 20%, focusing on personalized medicine and targeted therapies. Such collaborations not only enhance the understanding of prostate cancer but also facilitate the translation of research findings into clinical practice. The synergy created through these partnerships is likely to foster innovation and drive growth within the prostate cancer market. ### Government Initiatives and Funding Government initiatives play a pivotal role in shaping the prostate cancer market in South Korea. Increased funding for cancer research and treatment programs has been observed, with the government allocating over $200 million annually to cancer-related initiatives. These funds are directed towards improving screening programs, enhancing treatment facilities, and supporting research into innovative therapies. Such initiatives not only bolster the healthcare infrastructure but also encourage collaboration between public and private sectors, fostering advancements in the prostate cancer market. The commitment to reducing cancer mortality rates is likely to stimulate growth in this sector. ### Increasing Awareness and Education The prostate cancer market in South Korea is experiencing growth due to heightened awareness and education regarding prostate health. Campaigns aimed at educating the public about the risks and symptoms of prostate cancer have led to an increase in early detection rates. This awareness is crucial, as early-stage diagnosis significantly improves treatment outcomes. In 2025, it is estimated that approximately 30% of men over 50 are aware of the importance of regular screenings, contributing to a more proactive approach to health management. The emphasis on education is likely to drive demand for diagnostic services and treatment options. ### Technological Advancements in Diagnostics Technological advancements in diagnostic tools are significantly impacting the prostate cancer market in South Korea. Innovations such as MRI-guided biopsies and advanced imaging techniques have improved the accuracy of prostate cancer detection. In 2025, it is projected that the adoption of these technologies will increase by 25%, enhancing the ability to identify cancer at earlier stages. This shift towards more precise diagnostics is likely to lead to better treatment planning and patient outcomes. As healthcare providers invest in state-of-the-art diagnostic equipment, the prostate cancer market is expected to expand, driven by the demand for effective and efficient diagnostic solutions. ## Future Outlook The [Prostate cancer Market](https://www.marketresearchfuture.com/reports/prostate-cancer-market-1580) in South Korea is poised for growth at 7.62% CAGR from 2025 to 2035, driven by advancements in diagnostics, treatment options, and increasing awareness. **New opportunities:** - Development of AI-driven diagnostic tools for early detection - Expansion of telemedicine services for remote patient monitoring - Investment in personalized medicine approaches for tailored therapies By 2035, the prostate cancer market is expected to achieve substantial growth and innovation. ## Segment Insights ### South Korea Prostate Cancer Market Segment Insights South Korea Prostate Cancer Market Segment Insights ### Prostate Cancer Market Type Insights Prostate Cancer Market Type Insights The South Korea [Prostate Cancer Market](../../../reports/prostate-cancer-market-1580)has gained significant attention due to the increasing prevalence of prostate cancer among the male population in the region. Among the various types of prostate cancer, Prostate Adenocarcinoma represents the majority holding regarding cases, making it the most common type and thus a focal point for research and treatment. This cancer type is characterized by its slow growth, allowing for various management strategies, which is crucial given that many patients are diagnosed at an early stage and opt for active surveillance. The healthcare infrastructure in South Korea, alongside advancements in diagnostic technologies, has significantly improved the early detection rates of Prostate Adenocarcinoma, enabling timely intervention. Moreover, Small Cell Carcinoma is a less common but aggressive type of prostate cancer, presenting unique challenges in terms of treatment due to its rapid progression. The need for effective and personalized therapy for managing Small Cell Carcinoma has led to increased investments in innovative therapeutic approaches, including targeted therapy and immunotherapy. As South Korea continues to emphasize healthcare innovation and precision medicine, there is a growing opportunity for advancements in the treatment landscape for both types of prostate cancer. The South Korea Prostate Cancer Market segmentation is likely to benefit from ongoing public health initiatives aimed at raising awareness about prostate health, leading to more men seeking timely medical advice and screening. Furthermore, the aging population in South Korea, which is expected to grow significantly, will likely contribute to an increase in prostate cancer incidences, driving market growth and research into these types over the coming years. Keeping pace with these demographic changes will be essential for effectively addressing the burden of prostate cancer in South Korea. ### Prostate Cancer Market Component Insights Prostate Cancer Market Component Insights The South Korea Prostate Cancer Market has been experiencing notable growth, particularly within the Component segment, which comprises Therapy and Diagnosis. The increasing prevalence of prostate cancer in South Korea, coupled with advancements in treatment technologies, has driven demand in the Therapy segment. Various therapeutic approaches, including hormone therapy and immunotherapy, are gaining traction due to their efficacy and improved patient outcomes.  Meanwhile, the Diagnosis segment is equally important, as early detection significantly enhances treatment success rates.Innovative diagnostic tools and techniques, such as biopsy and imaging, are being adopted, reflecting a growing focus on precision medicine. The emphasis on personalized care is shaping the landscape of the South Korea Prostate Cancer Market, creating opportunities for new developments and partnerships in the industry. Additionally, rising awareness about prostate cancer and government initiatives aimed at improving screening and treatment infrastructure further support this market segment's expansion. Overall, the segmentation in the South Korea Prostate Cancer Market highlights an evolving landscape driven by advancements in both therapeutic and diagnostic capabilities. ### Prostate Cancer Market End-User Insights Prostate Cancer Market End-User Insights The South Korea Prostate Cancer Market has seen a remarkable focus on the End-User segment, which primarily includes Specialty Centers, Hospitals, and Clinics. As the prevalence of prostate cancer continues to rise in South Korea, there is an increasing reliance on these healthcare establishments for diagnosis and treatment. Specialty Centers play a crucial role in offering advanced care, utilizing state-of-the-art technologies that are increasingly important given the rising demand for targeted therapies.  Hospitals are also significant contributors to the South Korea Prostate Cancer Market, as they provide comprehensive services, including surgical interventions and radiation therapy, addressing a wide range of patient needs.Clinics, often the first point of contact, focus on early detection and management, facilitating timely interventions that are essential for improving patient outcomes. The growing population of older adults in South Korea further propels the demand for these services, emphasizing the importance of accessibility and quality of care within these facilities. As the market evolves, these End-User segments will continue to dominate, fulfilling critical healthcare needs in the ongoing fight against prostate cancer. ## Competitive Benchmarking The prostate cancer market in South Korea is characterized by a dynamic competitive landscape, driven by increasing incidence rates and advancements in treatment modalities. Key players such as Astellas Pharma (JP), Bayer AG (DE), and Johnson & Johnson (US) are actively shaping the market through strategic initiatives focused on innovation and regional expansion. Astellas Pharma (JP) emphasizes its commitment to research and development, particularly in novel therapies, while Bayer AG (DE) leverages its strong portfolio in oncology to enhance its market presence. Johnson & Johnson (US) adopts a multifaceted approach, integrating digital health solutions into its treatment offerings, thereby enhancing patient engagement and outcomes. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the prostate cancer market appears moderately fragmented, with several key players exerting influence. This fragmentation allows for diverse treatment options, yet the presence of major companies ensures a robust competitive dynamic that fosters continuous improvement and innovation. In October 2025, Astellas Pharma (JP) announced a strategic partnership with a leading South Korean biotechnology firm to co-develop a novel prostate cancer therapy. This collaboration is significant as it not only enhances Astellas' research capabilities but also aligns with the growing trend of leveraging local expertise to accelerate drug development. Such partnerships are likely to yield innovative solutions tailored to the specific needs of the South Korean market. In September 2025, Bayer AG (DE) launched a new digital platform aimed at improving patient access to prostate cancer treatments. This initiative reflects Bayer's commitment to integrating technology into healthcare, potentially transforming patient experiences and treatment adherence. By enhancing accessibility, Bayer positions itself as a leader in patient-centric care, which may strengthen its competitive edge in the market. In August 2025, Johnson & Johnson (US) expanded its oncology portfolio by acquiring a promising prostate cancer therapy from a smaller biotech company. This acquisition underscores Johnson & Johnson's strategy of bolstering its product offerings through targeted investments, which may enhance its market share and provide patients with more comprehensive treatment options. Such strategic moves indicate a trend towards consolidation in the market, as larger firms seek to integrate innovative therapies into their existing portfolios. As of November 2025, current competitive trends in the prostate cancer market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming pivotal, as companies recognize the value of collaboration in driving innovation and improving patient outcomes. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift may redefine market dynamics, emphasizing the importance of adaptability and forward-thinking strategies in a rapidly changing healthcare landscape. ## Recent News & Developments Recent developments in the South Korea Prostate Cancer Market have demonstrated significant progress in treatment options and research initiatives. Samsung Biologics is focusing on the development of biologics for prostate cancer therapeutics, while Pfizer and AbbVie continue to expand their portfolios of androgen receptor inhibitors. In October 2023, Roche launched a new immunotherapy that aims to enhance treatment efficacy for advanced prostate cancer patients.  Current affairs indicate a steady growth in the market valuation, driven by increasing prostate cancer prevalence and advancements in targeted therapies. The integration of digital health technologies is becoming prevalent, with companies like Johnson and Johnson and Eli Lilly investing in innovative solutions for patient monitoring and management.  In terms of mergers and acquisitions, Bayer completed its acquisition of a biotech firm specializing in prostate cancer therapies in September 2023, which is anticipated to strengthen its R&D capabilities. Major happenings over the past few years include the establishment of national guidelines in March 2021 for prostate cancer screening and management by the Korean Urological Association, reflecting the government's commitment to improving patient outcomes and bolstering the healthcare infrastructure. ## Report Scope | MARKET SIZE 2024 | 183.85(USD Million) | | --- | --- | | MARKET SIZE 2025 | 197.86(USD Million) | | MARKET SIZE 2035 | 412.4(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.62% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Astellas Pharma (JP), Bayer AG (DE), Johnson & Johnson (US), Pfizer Inc. (US), Novartis AG (CH), Merck & Co. (US), Sanofi (FR), Ipsen S.A. (FR), Eli Lilly and Company (US) | | Segments Covered | Type, Component, End User | | Key Market Opportunities | Emerging diagnostic technologies enhance early detection and treatment options in the prostate cancer market. | | Key Market Dynamics | Rising demand for advanced diagnostic tools drives innovation in the prostate cancer market in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current market valuation of the prostate cancer market in South Korea as of 2024?** A: The market valuation was $183.85 Million in 2024. **Q: What is the projected market valuation for the prostate cancer market in South Korea by 2035?** A: The projected valuation for 2035 is $412.4 Million. **Q: What is the expected CAGR for the South Korea prostate cancer market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 7.62%. **Q: Which types of prostate cancer are included in the market segments?** A: The market segments include Prostatic Adenocarcinoma and Small Cell Carcinoma. **Q: What were the market values for Prostatic Adenocarcinoma and Small Cell Carcinoma in 2024?** A: In 2024, Prostatic Adenocarcinoma was valued at $130.0 Million, while Small Cell Carcinoma was valued at $53.85 Million. **Q: What are the key components of the prostate cancer market in South Korea?** A: The key components are Therapy and Diagnosis. **Q: What were the market values for Therapy and Diagnosis in 2024?** A: In 2024, Therapy was valued at $120.0 Million, and Diagnosis was valued at $63.85 Million. **Q: Who are the leading players in the South Korea prostate cancer market?** A: Key players include Astellas Pharma, Bayer AG, Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Sanofi, Ipsen S.A., and Eli Lilly and Company. **Q: What are the end-user segments in the prostate cancer market?** A: The end-user segments include Specialty Centers and Hospital & Clinics. **Q: What were the market values for Specialty Centers and Hospital & Clinics in 2024?** A: In 2024, Specialty Centers were valued at $40.0 Million, while Hospital & Clinics were valued at $143.85 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-prostate-cancer-market-56121*